Table 4 Complications, treatment pattern and clinical outcomes of included patients
From: Clinical characteristics of inpatients with coronavirus disease 2019 (COVID-19) in Sichuan province
Diagnosis | Disease severity | ||||
|---|---|---|---|---|---|
Suspected (n = 22) | Laboratory-confirmed (n = 147) | Non-severe (n = 122) | Severe (n = 25) | P value# | |
Complications | |||||
Any Complications | 2/19 (10·5) | 15/146 (10·3) | 3/122 (2·5) | 12/24 (50·0) | < 0·0001 |
Respiratory failure | 1/19 (5·3) | 9/146 (6·2) | 2/122 (1·6) | 7/24 (29·2) | < 0·0001 |
Secondary bacterial pneumonia | 0/19 (0·0) | 4/146 (2·7) | 0/122 (0·0) | 4/24 (16·7) | > 0·99* |
Coagulation disorders | 0/19 (0·0) | 2/146 (1·4) | 0/122 (0·0) | 2/24 (8·3) | 0·03* |
Metabolic acidosis | 0/19 (0·0) | 1/146 (0·7) | 0/122 (0·0) | 1/24 (4·2) | 0·16* |
Shock | 0/19 (0·0) | 1/146 (0·7) | 0/122 (0·0) | 1/24 (4·2) | 0·16* |
Bacteremia or Sepsis | 1/19 (5·3) | 2/146 (1·4) | 0/122 (0·0) | 2/24 (8·3) | 0·026* |
Acute lung injury or ARDS | 0/19 (0·0) | 1/146 (0·7) | 0/122 (0·0) | 1/24 (4·2) | 0·16* |
Acute renal injury | 0/19 (0·0) | 0/146 (0·0) | 0/122 (0·0) | 0/24 (0·0) | ·· |
Treatment | |||||
Antiviral treatment | 11/14 (78·6) | 144/146 (98·6) | 119/121 (98·3) | 25/25 (100·0) | > 0·99* |
Ribavirin | 3/14 (21·4) | 14/146 (9·6) | 10/121 (8·3) | 4/25 (16·0) | 0·23 |
Interferon | 8/14 (57·1) | 95/146 (65·1) | 77/121 (63·6) | 18/25 (72·0) | 0·43 |
Lopinavir/Litonavir | 4/14 (28·6) | 133/146 (91·1) | 114/121 (94·2) | 19/25 (76·0) | 0·0040 |
Oseltamivir | 4/14 (28·6) | 22/146 (15·1) | 17/121 (14·1) | 5/25 (20·0) | 0·45 |
Antibiotic treatment | 9/16 (56·3) | 81/144 (56·3) | 59/120 (49·2) | 22/24 (91·7) | < 0·0001 |
Glucocorticoids | 1/15 (6·7) | 34/126 (27·0) | 16/101 (15·8) | 18/25 (72·0) | < 0·0001 |
Intravenous immunoglobulin therapy | 1/22 (4·5) | 8/147 (5·4) | 4/122 (3·3) | 4/25 (16·0) | 0·010 |
Oxygen therapy | 7/22 (31·8) | 59/147 (40·1) | 41/122 (33·6) | 18/25 (72·0) | < 0·0001 |
Mechanical ventilation (MV) | 2/22 (9·1) | 12/147 (8·2) | 0/122 (0·0) | 12/25 (48·0) | < 0·0001 |
Non-invasive MV | 2/22 (9·1) | 11/147 (7·5) | 0/122 (0·0) | 11/25 (44·0) | < 0·0001 |
Invasive MV | 1/22 (4·5) | 2/147 (1·4) | 0/122 (0·0) | 2/25 (8·0) | 0·029* |
ECMO | 0/22 (0·0) | 0/147 (0·0) | 0/122 (0·0) | 0/25 (0·0) | ·· |
CRRT | 0/22 (0·0) | 1/147 (0·7) | 0/122 (0·0) | 1/25 (4·0) | 0·17* |
Clinical outcomes | |||||
ICU admission | 0/22 (0·0) | 4/147 (2·7) | 0/122 (0·0) | 4/25 (16·0) | 0.00068 |
Death | 0/22 (0·0) | 0/147 (0·0) | 0/122 (0·0) | 0/25 (0·0) | ·· |